All In MedTech

Device Trial Radar · NCT07947498

Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction

Evaluation of the Prognostic Value of Long-term(2 Weeks) Electrocardiogram Analysis After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 2, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Chungnam National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
HUINNO Co., Ltd
First posted
Nov 19, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-center, single-group study will evaluate the prognostic value of long-term electrocardiographic monitoring in adults with acute myocardial infarction who undergo primary percutaneous coronary intervention. After written informed consent, eligible participants will have a MEMO Patch2 long-term Holter monitor applied on the day of, or the day after, the procedure and will wear it for 2 weeks. The study will classify high-risk arrhythmias detected during monitoring and compare long-term clinical outcomes according to arrhythmia classification.

Conditions

  • Acute Myocardial Infarction (AMI)
  • ST Elevation Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction
  • Cardiac Arrhythmias

Interventions

  • MEMO Patch2Device

    MEMO Patch2 is a detachable long-term Holter monitoring device. It will be applied on the day of, or the day after, primary percutaneous coronary intervention and worn for 2 weeks to record arrhythmias that may be missed by in-hospital monitoring. It will be removed at an outpatient visit, and the recordings will then be analyzed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Classification of High-Risk ArrhythmiasTime frame: At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.